Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Reaches New 1-Year High – Should You Buy?

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) shares reached a new 52-week high during trading on Monday . The stock traded as high as $52.25 and last traded at $52.25, with a volume of 0 shares. The stock had previously closed at $52.25.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada upgraded shares of Recordati Industria Chimica e Farmaceutica to a “hold” rating in a report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Price Performance

The firm’s fifty day simple moving average is $52.25 and its 200-day simple moving average is $51.87. The company has a quick ratio of 0.95, a current ratio of 1.36 and a debt-to-equity ratio of 0.73.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) last released its earnings results on Tuesday, July 30th. The company reported $0.70 earnings per share for the quarter. The company had revenue of $622.00 million for the quarter. Recordati Industria Chimica e Farmaceutica had a return on equity of 30.78% and a net margin of 17.41%.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.